Science Pool

Development of a Ligand for In Vivo Imaging of Mutant Huntingtin in Huntington’s Disease

Posted by Evotec on Mar 10, 2022 10:24:55 AM

Huntington´s Disease (HD) is a hereditary neurodegenerative disorder that is caused by a mutation in the huntingtin gene (mHTT) leading to deposition of pathologic protein aggregates in the brain.

This paper focuses on:

  • Visualization of mHTT aggregate expression by positron emission tomography (PET) in rodent HD model
  • Utility of the previously described novel PET imaging ligand CHDI-180 for detection of mHTT in rodent and post-mortem human HD brain
  • Ability of CHDI-180 to serve as functional response indicator for mHTT lowering therapies

GET THE PAPER

0 Comments Click here to read/write comments

Tags: Medicinal Chemistry, Articles & Whitepapers, Proteomics, Metabolomics & Biomarkers

American Biomanufacturing Summit

Posted by Evotec on Mar 10, 2022 9:23:23 AM

Date: 13 - 14 April 2022

Location: Hyatt Regency San Francisco Airport, San Francisco, CA, United States

Who's Attending? 

  • John Gunther, Senior Director Business Development at Just - Evotec Biologics

 

Presentation
Advanced Continuous Manufacturing Solutions to Accelerate Time to Clinic and Secure Cost-Effective Commercial Supply

  • The talk will be given by Magnus Schroeder, VP Process and Product Design at Just - Evotec Biologics


If you wish to meet with us in San Francisco, get in touch via the form below, we will be happy to arrange a meeting. We hope to see you there!

0 Comments Click here to read/write comments

Tags: Events, Evotec, Just Evotec Biologics

BSL3 High Throughput Screening Capabilities Fact Sheet

Posted by Evotec on Mar 8, 2022 5:05:24 PM

With more then 15 years of screening experience in anti-infectives, including antibacterials and antivirals, Evotec's medium throughput and high throughput screening expertise extends to BSL2+ and BSL3 containment level. 

DOWNLOAD NOW

0 Comments Click here to read/write comments

Tags: Fact Sheets, Hit & Target ID/Validation, Anti-Infectives

Learn about our Global Anti-Infective Platform

Posted by Evotec on Mar 2, 2022 3:02:49 PM
0 Comments Click here to read/write comments

Tags: SP Standalone

Read our Whitepaper: The Hollow Fibre Infection Model

Posted by Evotec on Mar 2, 2022 3:01:41 PM
0 Comments Click here to read/write comments

Tags: SP Standalone

Read our Fact Sheet on the Hollow Fibre Infection Model

Posted by Evotec on Mar 2, 2022 3:01:12 PM
0 Comments Click here to read/write comments

Tags: SP Standalone

Dive into our New Science Pool

Posted by Evotec on Mar 2, 2022 3:00:24 PM
0 Comments Click here to read/write comments

Tags: SP Standalone

E.SOLVE: Solving Bioavailability Challenges Fact Sheet

Posted by Evotec on Mar 2, 2022 1:37:10 PM

RZ_E_SOLVE-Logo+Tagline_211004_Screen_Blue-png

E.SOLVE is Evotec's solution to accelerate your journey to the clinic supporting your formulation strategy as early as possible from discovery to market approval.

Download this fact sheet to learn more about how E.SOLVE's full range of approaches improve solubilization and bioavailability to ensure that your API can progress through the drug discovery development pipeline faster.

DOWNLOAD

0 Comments Click here to read/write comments

Tags: IND Enabling, Fact Sheets, Formulation & CMC, Toxicology & Safety

Regulated ADMET Services Fact Sheet

Posted by Evotec on Mar 2, 2022 1:34:27 PM

Download this fact sheet to learn more about our regulatory ADMET services including:

  • Full support of development projects to fulfill and anticipate regulatory requirements
  • Accelerated development process with a full vision through all drug development phases up to filing
  • Dynamic team of expert scientists capable of handling projects of any complexity in regulated environment
  • Full integration with in-house bioanalytical and safety assessment groups
  • Tailored studies and programs based on specific client needs

DOWNLOAD

0 Comments Click here to read/write comments

Tags: Fact Sheets, ADME/DMPK, IND Enabling Studies/Preclinical Development, Toxicology & Safety

INDiGO-Select Fact Sheet

Posted by Evotec on Mar 2, 2022 1:34:15 PM

Learn more about how our INDiGO-Select services help in profiling and selecting your optimal clinical development candidate with:

  • Enhanced quality profile, speed of delivery, and probability of success of clinical candidates
  • Early identification of developability gaps and liabilities in selection process, enabling thorough
    de-risking of your candidate with flexible advanced lead optimization approaches
  • Managed by skilled discovery scientists and complemented by experienced drug development
    experts in CMC and preclinical development all under one roof

DOWNLOAD

0 Comments Click here to read/write comments

Tags: INDiGO, Fact Sheets, IND Enabling Studies/Preclinical Development, Toxicology & Safety, Clinical Development

All posts
© 2025 Evotec SE